Petosemtamab's phase 2 data in this setting should come by the year end.
ApexOnco Front Page
Recent articles
After ZW171's exit, ZW251 enters the clinic.
Can the company add a Car-T string to its stem cell transplant bow?
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Chengdu Kanghong's KH815 enters human testing this month.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
